Ascendis Pharma A/S
 | |
| | |
| Ascendis Pharma A/S | |
|---|---|
| Type | Public |
| Industry | BioTechnology |
| Founded | 2007 |
| Headquarters | Capital Region of Denmark, Denmark |
| Key people | 55 [1] |
| Investors | Gilde Healthcare Partners, OrbiMed, RA Capital Management, Rock Springs Capital, Sofinnova Partners, Sofinnova Ventures, TechnoStart, Venrock, Vivo Capital [2] |
| Number of employees | Jan Møller Mikkelsen (Co-Founder, President and CEO), Martin Auster (CBO), Michael Beckert (Chief Medical Officer (acting)), Thomas Soloway (CFO) |
Ascendis Pharma A/S is an emerging pharmaceutical company which is creating improved, patentable versions of both currently marketed drugs and high-value development-stage opportunities. The company is built upon a novel transient linker technology, TransientLink, which conjugates peptides, proteins and small molecules to a carrier molecule in a reversible fashion. This unique reversibility allows an unmodified active drug to be released (unlinked) in the body in a precise, time-controlled fashion, creating a long-acting effect. Conventional conjugation technologies are unable to achieve this type of slow-release mechanism because the polymer cannot de-link from the drug. [3]
Contents
Products
Ascendis Pharma A/S, a clinical stage biopharmaceutical company
- It develops various prodrug therapies to treat unmet medical needs.
- It is developing TransCon human growth hormone that has completed Phase II clinical trials in children and adults to treat growth hormone deficiency (GHD) and other indications
- TransCon Treprostinil that has completed Phase I clinical trial for the treatment of pulmonary arterial hypertension, a life-threatening disease characterized by elevated blood pressure in the pulmonary arteries.
- The company is also developing TransCon Peptides for the treatment of diabetes
- TransCon Ranibizumab, a compound to support injection of ranibizumab.
- It has strategic collaborations with Sanofi and Genentech
Controversies
None Reported
Top 5 Recent Tweets
| Date | Author | Comment |
|---|---|---|
| October 22, 2019 | AmericanBanking | Ascendis Pharma A/S’s $ASND “Outperform” Rating Reaffirmed at Wedbush https://t.co/Z0EdYSImtP #stocks |
| October 22, 2019 | WatchlistN | Wedbush Reaffirms “Outperform” Rating for Ascendis Pharma A/S $ASND https://t.co/HrqXzM4a8Z |
| October 22, 2019 | iitoLifeScience | Ascendis Pharma A/S Receives Orphan Designation for TransCon hGH for Pediatric Growth Hormone Deficiency in Europe… https://t.co/5aY1zEvJy2 |
| October 21, 2019 | NewsFromSPI | Ascendis Pharma A/S Receives Orphan Designation for TransCon™ hGH for the Treatment of Pediatric Growth Hormone Def… https://t.co/2bBJeggrJf |
| October 21, 2019 | HIV_AIDS_Bio | Ascendis Pharma AS Receives Orphan Designation for TransCon hGH for the Treatment of Pediatric Growth Hormone Defic… https://t.co/fn2BkIsdcl |
Top 5 Recent News Headlines
Top 5 Lifetime Tweets
Top 5 Lifetime News Headlines
- ↑ http://www.nasdaq.com/markets/ipos/company/ascendis-pharma-as-951656-77256
- ↑ https://www.crunchbase.com/organization/ascendis-pharma#/entity
- ↑ http://www.bionity.com/en/companies/14852/ascendis-pharma-a-s.html
- ↑ http://www.bloomberg.com/research/stocks/private/snapshot.asp?privcapid=39510693
Top Authors
Verification history
1,051 days ago- View all verifications
